Neuropace, Inc.: JPMorgan cuts to neutral from overweight; cuts target price to $9 from $20
NPCE•JPMorgan cut its rating on Neuropace to neutral from overweight and its target price to $9 from $20.
Related News
Mobility Global Inc: JP Morgan raises target price to $25 from $21
MBGL•
Piper Sandler cuts National Energy Services Reunited Corp. target price to $37 from $39
NESR•
Milestone Pharmaceuticals reports third-quarter 2026 financial results
MIST•
Xometry target price raised to $140 from $130
XMTR•
YETI Holdings: Raymond James cuts target price to $50 from $56
YETI•